A CROSS-SECTIONAL RESEARCH TO ASSESS & DIAGNOSE THE POSITIVE TREND OF HER – 2 RECEPTORS IN DUCTAL & LOBULAR CARCINOMA PATIENTS

Objective: This research is designed to diagnose HER – 2 positivity among the cases of breast cancers.

Methods: A Cross-sectional study suited to problem statement and nature of predicament and the entire process of study held at Services Hospital Lahore (February – December 2017) in the Surgical Department. The population of the research encapsulated a total number of one hundred and twenty successive females suffering from breast cancer. Furthermore, surgeons sent a tissue operation for the dire purpose of immune-histochemical (IHC) inquiry HER – 2/neu receptors and ER/PR receptors. Additionally, a thorough histopathological analysis plus subtype of tumour, histological status.

Results: All the one hundred and twenty female patients under research having breast cancer detected on histopathology with the help of their tissue sample suited themselves for this research. The age of research participants ranged from (31 – 55) years. Therefore, the total fifty female patients reported their Her-2/neu receptor positive of the total percentage of (42%). Whereas, ninety-four female came up with positive ER, 81 with positive PR receptor consequently. On histopathology, the greater part of the research patients was suffering from a tumor that was invasive ductal carcinoma type. The numbers were one hundred and eight (90%) of the total.  Moreover, obesity and HER – 2 Receptor have had no prominent association and the range of P was greater than (0.05) but the age of the patient drew a clear and significant association that range of P was less than (0.05).

Conclusion: This study lucidly portrayed a high degree of positive manifestation of Her – 2 receptors among the patients of breast cancer and have had a prominent association between Her – 2 receptors and their age. Therefore, research advises to check the status of Her – 2/neu receptor among all hospitalized breast cancer patients in consort with progesterone receptor and estrogen exclusively in young female patients.

Keywords: HER – 2/neu, Breast Carcinoma, ER/PR and Cancer.